COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D PXPX FLVFLV PVP-IPI BUBU BHBH BLBL CICI HC QHC Q NZNZ COCO More..
 
Home   
Share  
  OutcomesOutcomes
  Global AdoptionAdoption
  Submit FeedbackFeedback
00.250.50.7511.251.51.752+Rocco (RCT)-404%5.04 [0.24-104]ICU2/1940/198Improvement, RR [CI]TreatmentControlCadegiani88%0.12 [0.01-2.52]death0/3572/137Elalfy87%0.13 [0.06-0.27]viral+7/6244/51CT​1Silva (SB RCT)26%0.74 [0.14-3.85]viral+23 (n)13 (n)Rossignol (DB RCT)-206%3.06 [0.13-74.6]death1/1840/195Tau​2 = 1.61; I​2 = 63.5%Early treatment49%0.51 [0.12-2.27]10/82046/59449% improvementBlum (DB RCT)67%0.33 [0.07-1.50]death2/256/25Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment67%0.33 [0.07-1.50]2/256/2567% improvementAll studies58%0.42 [0.14-1.30]12/84552/61958% improvement6 nitazoxanide COVID-19 studiesc19nitazoxanide.com 8/2/211 CT: study uses combined treatmentTau​2 = 0.94; I​2 = 55.6%; Z = 1.51 (p = 0.066)Effect extraction pre-specifiedLower RiskIncreased Risk
4/20
Early Rossignol et al., medRxiv, doi:10.1101/2021.04.19.21255441 (Preprint) death, ↑206.0%, p=0.49 Early treatment with nitazoxanide prevents worsening of mild and moderate COVID-19 and subsequent hospitalization
Details   RCT with 184 outpatients treated with an extended release formulation of nitazoxanide, and 195 controls, showing lower hospitalization and progression to severe disease with treatment. There was one COVID-19 related death in the treatment..
3/5
Early Silva et al., medRxiv, doi:10.1101/2021.03.03.21252509 (Preprint) viral+, ↓26.5%, p=0.36 Efficacy of Nitazoxanide in reducing the viral load in COVID-19 patients. Randomized, placebo-controlled, single-blinded, parallel group, pilot study
Details   Small RCT with 23 nitazoxanide and 13 control patients showing significantly more patients achieved over 35% reduction in viral load from baseline. NCT04463264.
2/16
Early Elalfy et al., J. Med. Virol., doi:10.1002/jmv.26880 (Peer Reviewed) viral+, ↓86.9%, p<0.0001 Effect of a combination of Nitazoxanide, Ribavirin and Ivermectin plus zinc supplement (MANS.NRIZ study) on the clearance of mild COVID-1
Details   Non-randomized controlled trial with 62 mild and early moderate patients with home treatment with ivermectin + nitazoxanide + ribavirin + zinc, showing significantly faster viral clearance.
1/22
Late Blum et al., EClinicalMedicine, doi:10.1016/j.eclinm.2021.100981 (preprint 1/22) (Peer Reviewed) death, ↓66.7%, p=0.25 Nitazoxanide superiority to placebo to treat moderate COVID-19 – A Pilot prove of concept randomized double-blind clinical trial
Details   RCT with 25 nitazoxanide patients and 25 control patients, showing improved virological and clinical outcomes with treatment. Authors also perform an in vitro study in Vero E6 cells showing 90% inhibition with 0.5µM, with no cytotoxicity..
11/4
Early Cadegiani et al., New Microbes and New Infections, doi:10.1016/j.nmni.2021.100915 (preprint 11/4/2020) (Peer Reviewed) death, ↓87.8%, p=0.08 Early COVID-19 Therapy with azithromycin plus nitazoxanide, ivermectin or hydroxychloroquine in Outpatient Settings Significantly Improved COVID-19 outcomes compared to Known outcomes in untreated patients
Details   Comparison of HCQ, nitazoxanide, and ivermectin showing similar effectiveness for overall clinical outcomes in COVID-19 when used before seven days of symptoms, and overwhelmingly superior compared to the untreated COVID-19 population, ev..
10/23
Early Rocco et al., European Respiratory Journal, doi:10.1183/13993003.03725-2020 (preprint 10/23/20) (Peer Reviewed) ICU, ↑404.1%, p=0.24 Early use of nitazoxanide in mild Covid-19 disease: randomized, placebo-controlled trial (preprint 10/23)
Details   RCT 392 patients, median treatment delay 5 days, showing improved viral recovery at 5 days. Symptom recovery was no different at 5 days, and the treatment arm had two ICU admissions compared to zero for control. There were no serious adve..
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop to submit images   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit    
Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Molnupiravir
Nitazoxanide
Povidone-Iodine
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin C
Vitamin D
Zinc

Feedback